Biochemical liver function test parameter levels in relation to treatment response in liver metastatic colorectal patients treated with FOLFOX4 with or without bevacizumab
Denić, K.; Tarabar, D.; Obradovic, S.; Ristić, M.; Spasić, J.; Radosavljević, D.; Ugrešić, N.
Srpski Arhiv Za Celokupno Lekarstvo 144(11-12): 615-620
2016
ISSN/ISBN: 0370-8179 PMID: 29659222 Document Number: 690102
Combined use of bevacizumab and conventional anticancer drugs leads to a significant The objective of our study was to examine whether clinical outcome in patients with liver The study included 96 patients with untreated liver metastatic CRC who received FOLFOX4 In the group of patients with disease regression the post-treatment levels of aspartate aminotransferase, Treatment responses are not completely associated with the level of liver function test parameters.
Document emailed within 1 workday
Related Documents
Mizota, A.; Shitara, K.; Kondo, C.; Nomura, M.; Yokota, T.; Takahari, D.; Ura, T.; Muro, K. 2011: FOLFOX plus cetuximab for a patient with metastatic colorectal cancer with icterus due to multiple liver metastases Gan to Kagaku Ryoho. Cancer and ChemoTherapy 38(7): 1205-1208Ben Slama, S.; Bacha, D.; Sassi, A.; Khadhar, A.; Bayar, R.; Bouraoui, S.; Lahmar, A. 2017: Pathological response of colorectal liver metastases treated after induction treatment La Tunisie Medicale 95(10): 854-858
Kikuoka, S.; Miura, T.; Takeuchi, I.; Miura, T.; Akamatsu, N.; Ishida, F.; Ozawa, F.; Moriguchi, M. 2009: Switching to direct intrahepatic arterial infusion of 5-FU after a progression of liver metastases from colorectal carcinoma treated with systemic infusion of FOLFOX Gan to Kagaku Ryoho. Cancer and ChemoTherapy 36(12): 2036-2038
Hasegawa, J.; Noura, S.; Hirota, M.; Matsumura, T.; Yasuyama, A.; Takata, A.; Koga, C.; Murakami, M.; Kameda, C.; Oda, N.; Kawabata, R.; Morishima, H.; Shimizu, J.; Matsunami, N. 2016: A Case of Metastatic Colorectal Cancer Refractory to Standard Chemotherapies Treated with TAS-102 with Bevacizumab Gan to Kagaku Ryoho. Cancer and ChemoTherapy 43(12): 2289-2291
des Guetz, G.; Mariani, P.; Cucherousset, J.; Benamoun, M.; Lagorce, C.; Sastre, X.; Le Toumelin, P.; Uzzan, B.; Perret, G.Y.; Morere, J.F.; Breau, J.L.; Fagard, R.; Schischmanoff, P.O. 2007: Microsatellite instability and sensitivitiy to FOLFOX treatment in metastatic colorectal cancer Anticancer Research 27(4c): 2715-2719
Takano, J.; Matsuhashi, N.; Takahashi, T.; Tanahashi, T.; Matsui, S.; Imai, H.; Tanaka, Y.; Yamaguchi, K.; Yoshida, K. 2018: A Case of Metastatic Colorectal Cancer with Brain Metastasis Treated with Combined TFTD and Bevacizumab Therapy Gan to Kagaku Ryoho. Cancer and ChemoTherapy 45(2): 318-320
Fujita, K. 1939: Experimental study on the mutual relation between the lung function and the liver function. I. The liver function in cases of disturbance of the pulmonal function Jap Jour Gastroenterol 11(3/4): 152-157
Feng, Y-Mei.; Chen, M.; Li, J.; Liu, X-Mei.; Dai, L.; Meng, Q-Hua. 2010: Association between PCT levels and liver function in liver cirrhosis patients Zhonghua Shi Yan he Lin Chuang Bing du Xue Za Zhi 24(6): 468-469
Wang, X.-Y.; Niu, C.-L.; Zhang, L.; Jin, L.; Li, N.; Cao, W.-X.; Qin, H.-L.; Yang, Y.; Tong, B.-d.; Li, J.-S. 2011: Effect of enteral nutrition on liver function and inflammatory response after abdominal operation in patients complicated with liver dysfunction Zhonghua Wei Chang Wai Ke Za Zhi 14(5): 336-339
Katayose, Y.; Yamamoto, K.; Nakagawal, K.; Takemura, S.; Takahashi, M.; Nakamura, R.; Shimamura, H.; Rikiyama, T.; Egawa, S.; Yoshda, H.; Motoi, F.; Naitoh, T.; Unno, M. 2015: Feasibility Assessment of Modified FOLFOX-6 as adjuvant treatment after resection of liver metastases from colorectal cancer: analyses of a multicenter phase II clinical trial (Miyagi-HBPCOG Trial-001) Hepato-Gastroenterology 62(138): 303-308
Sehnalová, I.; Říhová, B.; Demlová, R. 2019: Bevacizumab treatment in metastatic colorectal carcinoma - an economic perspective Ceska a Slovenska Farmacie: Casopis Ceske Farmaceuticke Spolecnosti a Slovenske Farmaceuticke Spolecnosti 68(2): 43-47
Imaizumi, H.; Ishibashi, K.; Okada, N.; Tajima, Y.; Amano, K.; Hatano, S.; Kuwabara, K.; Sobajima, J.; Ishiguro, T.; Ohsawa, T.; Kumamoto, K.; Kumagai, Y.; Haga, N.; Ishida, H. 2012: Clinical outcomes in refractory colorectal cancer patients with wild-type K-ras treated with bevacizumab and oxaliplatin-based chemotherapy as a first-line treatment Gan to Kagaku Ryoho. Cancer and ChemoTherapy 39(12): 2185-2188
Fassati, P.; Horejsí, J.; Motejlová, A.; Spízek, J.; Fassati, M.; Jezková, Z. 1982: The relationship of the humoral immunologic reaction - IgG, IgA and IgM levels - and biochemical indicators of liver function in cirrhosis Vnitrni Lekarstvi 28(11): 1055-1060
Huang, C.-x.; Li, Z.-y.; Jiang, Y.-q.; Duan, G.-l.; Wang, Q.-q. 2010: Influence of FOLFOX regimen on the immunologic function in patients with advanced colorectal cancer Zhonghua Wei Chang Wai Ke Za Zhi 13(9): 661-663
Arakawa, S.; Horiguchi, A.; Tomishige, H.; Kawabe, N.; Nagata, H.; Ishihara, S.; Ito, M.; Asano, Y.; Ito, R.; Isetani, M.; Shimizu, K.; Kamio, K.; Kawai, T.; Yasuoka, H.; Imaeda, Y. 2018: Safety and Efficacy of TAS-102 with Bevacizumab for the Treatment of Unresectable Metastatic Colorectal Cancer - A Case Report Gan to Kagaku Ryoho. Cancer and ChemoTherapy 45(4): 649-651
Durczyński, A.; Szymański, D.; Nowicki, Mł.; Hogendorf, P.; Stefańczyk, L.; Strzelczyk, J. 2011: Two-stage liver resections with portal branch ligation--a novel treatment strategy for patients with initially irresectable, bilobar colorectal liver metastases Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego 30(178): 268-271
Koike, J.; Ushigome, M.; Funahashi, K.; Shiokawa, H.; Kaneko, T.; Arai, K.; Matsuda, S.; Kagami, S.; Suzuki, T.; Kurihara, A.; Shimada, H.; Kaneko, H. 2014: Significance of KRAS mutation in patients receiving mFOLFOX6 with or without bevacizumab for metastatic colorectal cancer Hepato-Gastroenterology 61(136): 2222-2226
Stahel, E.; Tanner, M.; Gyr, N.; Weiss, N.; Hess, C.; Betschart, B. 1984: Seroepidemiology of hepatitis B virus in rural Tanzania: relation of hepatitis B markers and liver function tests in patients with clinical liver disease and in healthy controls East African Medical Journal 61(11): 806-811
Shirato, T.; Aoki, T.; Yazawa, M. 2011: Surgical treatment for metastatic lung cancer treated with bevacizumab Kyobu Geka. Japanese Journal of Thoracic Surgery 64(7): 579-581
Chen, C.; Sun, P.; Ye, S.; Weng, H.-W.; Dai, Q.-S. 2014: Hypertension as a predictive biomarker for efficacy of bevacizumab treatment in metastatic colorectal cancer: a meta-analysis Journal of Buon: Official Journal of the Balkan Union of Oncology 19(4): 917-924